

CELGENE CORP /DE/  
Form 8-K  
January 06, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **January 6, 2015**

**CELGENE CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-34912**  
(Commission File Number)

**22-2711928**  
(IRS Employer Identification No.)

**86 Morris Avenue, Summit, New Jersey**  
(Address of principal executive offices)

**07901**  
(Zip Code)

Registrant's telephone number, including area code: **(908) 673-9000**

Edgar Filing: CELGENE CORP /DE/ - Form 8-K

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 8.01 OTHER EVENTS**

On January 6, 2015, Celgene Corporation announced that it will present a business update on the Company in addition to unaudited 2014 financial results and an updated financial outlook at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 10:30 a.m. EST.

Attached hereto and incorporated herein by reference as Exhibit 99.1 is the Press Release announcement.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

Exhibit 99.1 Press Release dated January 6, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELGENE CORPORATION**

Date: January 6, 2015

By:

/s/ Peter N. Kellogg  
Peter N. Kellogg  
Executive Vice President  
Chief Financial Officer  
(principal financial and accounting officer)

**EXHIBIT INDEX**

Exhibit No.	Description
99.1	Press Release dated January 6, 2015.